RTOG 3506
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with PostProstatectomy PSA Recurrences with Aggressive
Trial overview
| Disease | Prostate cancer treatment & diagnosis |
| Topic | RTOG 3506 |
| Description | Primary Objective The primary goal of this study is to determine whether, in men with postprostatectomy PSA (prostate specific antigen) recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced androgen deprivation therapy (ADT), consisting of enzalutamide (MDV3100) and a GnRH analog, will improve progression-free survival compared to SRT with standard GnRH analog -based ADT. |
| Physicians | Dr. Thomas BoikeMD Radiation Oncologist Works at 3 centers.Dr. Larry L. KestinMD, FACR Radiation Oncologist Works at 3 centers.Dr. Alvaro A. MartinezMD, FACR, FABS, FASTRO Radiation Oncologist Works at 5 centers.Dr. Frank A. ViciniMD, FACR, FASTRO Radiation oncologist Works at 3 centers.Dr. John Vito AntonucciMD Radiation Oncologist Works at 4 centers.Dr. Michael I. GhilezanMD, PhD Radiation Oncologist Works at 4 centers.Dr. Eduardo B. FernandezMD, PhD, FACRO, FASTRO Radiation Oncologist Works at 4 centers. |